[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n GgtrIzab9oGSgd2GfMRbbu3Vn48yxLjiXD6AZpcKnZnHPdVVvspeRACwi7YKt9XR\n RtOurpYnaKtDvzuU7/k9yA==\n\n', u'0001193125-04-163968.txt : 20040929\n', u'0001193125-04-163968.hdr.sgml : 20040929\n', u'20040929154655\nACCESSION NUMBER:\t\t0001193125-04-163968\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040929\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040929\nDATE AS OF CHANGE:\t\t20040929\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tNEOGEN CORP\n\t\tCENTRAL INDEX KEY:\t\t\t0000711377\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]\n\t\tIRS NUMBER:\t\t\t\t382367843\n\t\tSTATE OF INCORPORATION:\t\t\tMI\n\t\tFISCAL YEAR END:\t\t\t0531\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-17988\n\t\tFILM NUMBER:\t\t041052756\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t620 LESHER PLACE\n\t\tCITY:\t\t\tLANSING\n\t\tSTATE:\t\t\tMI\n\t\tZIP:\t\t\t48912\n\t\tBUSINESS PHONE:\t\t5173729200\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 2:\t\t620 LESHER PLACE\n\t\tCITY:\t\t\tLANSING\n\t\tSTATE:\t\t\tMI\n\t\tZIP:\t\t\t48912\n', u'\n', u'\n', u'8-K\n', u'1\n', u'd8k.htm\n', u'FORM 8-K\n', u'\n', u'Form 8-K', u'\n', u' ', u'UNITED STATES ', u' ', u'SECURITIES AND EXCHANGE COMMISSION ', u' ', u'Washington, D.C. 20549 ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'FORM 8-K ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'CURRENT REPORT ', u' ', u'Pursuant to Section 13 OR 15(d) of ', u' ', u'The Securities Exchange Act of 1934 ', u' ', u'\xa0', u' ', u'Date of\nReport (Date of earliest event reported) September 29, 2004 ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'NEOGEN CORPORATION ', u' ', u'(Exact name of registrant as specified in its charter) ', u' ', u'\xa0', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'MICHIGAN', u'\n', u'\xa0', u'\n', u'0-17988', u'\n', u'\xa0', u'\n', u'38-2367843', u'\n', u'\n', u' ', u'(State or other jurisdiction', u' ', u'of incorporation)', u'\n', u'\xa0', u'\n', u'(Commission File Number)', u'\n', u'\xa0', u'\n', u' ', u'(IRS Employer', u' ', u'Identification No.)', u'\n', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'620 Lesher Place Lansing, Michigan', u'\n', u'\xa0', u'\n', u'48912', u'\n', u'\n', u'(Address of principal executive offices)', u'\n', u'\xa0', u'\n', u'(Zip Code)', u'\n', u' ', u'\xa0', u' ', u'Registrant\x92s\ntelephone number, including area code 517-372-9200 ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'(Former name or former address, if changed since last report.) ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Check the\nappropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'Item 2.02 Results of Operations and Financial Condition ', u' ', u'\xa0', u' ', u'On September 29, 2004, Neogen Corporation issued a press release announcing\nresults of operations for the fiscal quarter ended August 31, 2004. A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed \x93filed\x94 for purposes of Section 18 of\nthe Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.\n', u' ', u'\xa0', u' ', u'Item 9.01 Financial Statements and Exhibits ', u' ', u'\xa0', u' ', u'(c) Exhibits ', u' ', u'\xa0', u' ', u'99.1 Press Release dated September 29, 2004 ', u'\n', u'\n', u'\n', u'SIGNATURES ', u' ', u'\xa0', u'\n', u'Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized. ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'NEOGEN CORPORATION', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(Registrant)', u'\n', u'\n', u' ', u'Date: September 29, 2004', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u' ', u'/s/ Richard R. Current', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Richard R. Current', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Vice President & CFO', u'\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'dex991.htm\n', u'PRESS RELEASE\n', u'\n', u'Press Release', u'\n', u'Exhibit 99.1 ', u' ', u'\xa0', u' ', u'FOR IMMEDIATE RELEASE ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'CONTACT:', u'\n', u'\xa0', u'\n', u'Richard R. Current', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Vice President & CFO', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'517/372-9200', u'\n', u' ', u'\xa0', u' ', u'Neogen reports\n30% increase in operating income ', u' ', u'\xa0', u' ', u'LANSING, Mich., Sept. 29, 2004 \x96\nNeogen Corporation (Nasdaq: NEOG) announced today that its operating income for the first quarter of its 2005 fiscal year, which ended Aug. 31, jumped 30% from the previous year\x92s first quarter. Neogen\x92s first quarter revenues were\n$15,212,000 \x97 a 24% increase compared to the prior year. ', u' ', u'\xa0', u' ', u'First quarter\nnet income per share was $0.19 as compared with $0.16 for the same period last year. Neogen\x92s quarterly net income increased 22% to $1,584,000 from $1,302,000 in FY 2004. The quarter marked the 46th consecutive profitable quarter from\noperations for the company, and was the 51st of the past 55 quarters when Neogen reported revenue increases as compared with the previous year. ', u' ', u'\xa0', u' ', u'\x93The first quarter was a great start for our new fiscal year,\x94 said James Herbert, Neogen\x92s president. \x93We continued our remarkable quarter-to-quarter\nsuccess of consistent growth in sales and profits, and also made significant progress in implementing our plan to ensure long-term growth. I\x92m very proud of our management team and employee group.\x94 ', u' ', u'\xa0', u' ', u'The first quarter also saw Neogen continue its progress toward controlling costs to improve\noperating results. Sales and marketing expenses dropped to 21% of sales from last year\x92s 24%. General and administrative expenses remained within Neogen\x92s target range \x97 under 8% of sales, and gross margins increased for the third\nstraight quarter to 49.3% of sales. As a result, the company\x92s operating income increased to 16% of sales compared with 15% in the prior year. ', u' ', u'\xa0', u' ', u'Neogen\x92s Animal Safety Division led the company\x92s first quarter revenue increase, with sales up 50% from $5,334,000 in FY 2004 to $8,012,000 in FY 2005. The\nNovember 2003 acquisitions of Hacco and Hess & Clark contributed substantially to the increase. However, the division also saw significant sales growth in its veterinary instrument products, up 20% over last year, and sales of Neogen\x92s\nproprietary K-Blue', u'\xae', u' substrate, which was up 45%.\nSales growth of more than 40% was also achieved for both BotVax', u'\xae', u' B and EqStim', u'\xae', u',\nNeogen\x92s unique vaccines sold primarily to the professional equine market. ', u' ', u'\xa0', u' ', u'Integrating Hacco\x92s rodenticides into Neogen\x92s sales and marketing group yielded a 18% sales increase when compared to the same quarter under previous ownership. Neogen\x92s veterinary instrument revenues were bolstered by\ncontinuing improvement in sales to veterinary retailers, including Tractor Supply Company. Sales of Neogen\x92s D3', u'\x99', u' detectable veterinary needles experienced a strong increase as the needles\x92 unique combination of durability and detectability continues to gain\nmarket acceptance. ', u' ', u'\xa0', u' ', u'\x93The quarter provided solid indications that our\ncost-saving initiatives are yielding results,\x94 said Lon Bohannon, Neogen\x92s chief operating officer. ', u'\n', u'\n', u'\n', u'\n', u'\n', u'\x93We made some strategic decisions in the previous fiscal year that had a short-term adverse impact on our earnings knowing we would achieve long-term\nbenefits. In our first quarter, we started to realize some of those benefits.\x94 Neogen\x92s Food Safety Division first quarter revenues were up 4.4% compared to the prior year. Lower overall sales for general sanitation products and tests to\ndetect naturally occurring toxins were offset by sizable increases in sales of Acumedia dehydrated culture media products, and food safety products to international markets. Acumedia sales increased 38% overall, led by strong sales into industrial,\npharmaceutical and food safety markets. International food safety sales jumped 33%, led by a 38% sales growth in Latin America for products such as rapid test kits for genetically modified soybeans and test kits to detect harmful pathogens, such as\n', u'Listeria', u'. ', u' ', u'\xa0', u' ', u'Increasing sales of Acumedia products led Neogen to a\ndecision to consolidate its outdated Baltimore dehydrated culture media operations into newly-renovated space in its Lansing, Mich., facilities. The new facilities and processing equipment are expected to dramatically improve operating efficiency,\nand increase capacity by 300 to 400%. Production of Acumedia products is expected to be fully integrated into the Lansing facilities before the end of Neogen\x92s second fiscal quarter. The move is not expected to have a material effect on\nearnings for the current fiscal year. ', u' ', u'\xa0', u' ', u'\x93Our solid first quarter results\nenabled Neogen to improve on its already strong financial position,\x94 said Richard Current, Neogen\x92s chief financial officer. \x93Positive cash flows allowed us to pay down $1.5 million of long-term debt and invest more than $700,000 in\nnew facilities and equipment.\x94 ', u' ', u'\xa0', u' ', u'Neogen Corporation develops and markets\nproducts dedicated to food and animal safety. The company\x92s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues,\nplant diseases and sanitation concerns. Neogen\x92s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. ', u' ', u'\xa0', u' ', u'NEOGEN CORPORATION SUMMARIZED UNAUDITED CONSOLIDATED OPERATING DATA\n', u' ', u'(In thousands, except for percentages and per share amounts) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'Quarter ended Aug.\xa031', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Revenue', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Food Safety', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'7,200', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'6,899', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Animal Safety', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'8,012', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,334', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Total revenue', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'15,212', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,233', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Cost of sales', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'7,707', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,973', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Gross margin', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'7,505', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,260', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Other expenses', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Sales & marketing', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'3,206', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,923', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Administrative', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'1,151', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'787', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Research & development', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'718', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'676', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Total other expenses', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'5,075', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,386', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Operating income', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,430', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,874', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Other revenue', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'(11', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'108', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Income before tax', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,419', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,982', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Income tax', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'835', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'680', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Net income', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,584', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,302', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Net income per diluted share', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'0.19', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.16', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Other information:', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Shares to calculate per share', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'8,468', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,211', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Depreciation & amortization', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'434', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'301', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Interest expense', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'24', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97\xa0\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Gross margin (% of sales)', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'49.3', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'51.2', u'\n', u'%', u'\n', u'\n', u' ', u'Operating income (% of sales)', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'16.0', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15.3', u'\n', u'%', u'\n', u'\n', u' ', u'Revenue increase vs. FY 2004', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'24.3', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Net income increase vs. FY 2004', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'21.7', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'NEOGEN CORPORATION SUMMARIZED UNAUDITED CONSOLIDATED BALANCE SHEET DATA ', u' ', u'(In thousands) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'Aug. 31', u'2004', u'\n', u'\xa0\xa0', u'\n', u'May 31', u'2004', u'\n', u'\n', u' ', u'Assets', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Current assets', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Cash & investments', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,585', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,696', u'\n', u'\n', u' ', u'Accounts receivable', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'10,357', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'9,924', u'\n', u'\n', u' ', u'Inventory', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'12,383', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'12,374', u'\n', u'\n', u' ', u'Other current assets', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'1,917', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,281', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u' ', u'Total current assets', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'26,242', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'26,275', u'\n', u'\n', u' ', u'Property & equipment', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'11,328', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'10,952', u'\n', u'\n', u' ', u'Goodwill & other assets', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'22,664', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'22,748', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u' ', u'Total assets', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'60,234', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'59,975', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Liabilities & Stockholders\x92 Equity', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Current liabilities', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Accounts payable', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'2,829', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'3,063', u'\n', u'\n', u' ', u'Other current liabilities', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,657', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,593', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u' ', u'Total current liabilities', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'5,486', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'5,656', u'\n', u'\n', u' ', u'Other liabilities', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'4,952', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'6,477', u'\n', u'\n', u' ', u'Stockholders\x92 equity\x97shares out 8,087 in \x9105 & 8,010 in \x9104', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'49,796', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'47,842', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u' ', u'Total liabilities & stockholders\x92 equity', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'60,234', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'59,975', u'\n', u' ', u'\xa0', u' ', u'Certain portions of\nthis news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially\nfrom historical results or those expected depending on a variety of factors listed in Management\x92s Discussion and Analysis of Financial Condition and Results of Operations in the Company\x92s most recently filed Form 10-K. ', u' ', u'\xa0', u' ', u'### ', u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']